| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Pavan Srivastava, Prabhash Nath Tripathi, Piyoosh Sharma, Sushant Kumar Shrivastav. Design, synthesis, and evaluation of novel N-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat Alzheimer's disease. Bioorganic & medicinal chemistry. vol 27. issue 16. 2020-09-15. PMID:31288978. |
design, synthesis, and evaluation of novel n-(4-phenoxybenzyl)aniline derivatives targeting acetylcholinesterase, β-amyloid aggregation and oxidative stress to treat alzheimer's disease. |
2020-09-15 |
2023-08-13 |
Not clear |
| Fatemeh Ansari, Jahan B Ghasemi, Ali Niaz. Three Dimensional Quantitative Structure Activity Relationship and Pharmacophore Modeling of Tacrine Derivatives as Acetylcholinesterase Inhibitors in Alzheimer's Treatment. Medicinal chemistry (Shariqah (United Arab Emirates)). vol 16. issue 2. 2020-09-14. PMID:31092184. |
three dimensional quantitative structure activity relationship and pharmacophore modeling of tacrine derivatives as acetylcholinesterase inhibitors in alzheimer's treatment. |
2020-09-14 |
2023-08-13 |
Not clear |
| Yameng Han, Zhongju Ye, Fuyan Wang, Tianyu Chen, Lin Wei, Langxing Chen, Lehui Xia. Single-particle enumeration-based ultrasensitive enzyme activity quantification with fluorescent polymer nanoparticles. Nanoscale. vol 11. issue 31. 2020-09-11. PMID:31353389. |
acetylcholinesterase (ache) plays a vital role in nerve conduction through rapidly hydrolyzing the neurotransmitter acetylcholine (ach) and is correlated with alzheimer's disease. |
2020-09-11 |
2023-08-13 |
human |
| b' Martin Kr\\xc3\\xa1tk\\xc3\\xbd, \\xc5\\xa0\\xc3\\xa1rka \\xc5\\xa0t\\xc4\\x9bp\\xc3\\xa1nkov\\xc3\\xa1, Neto-Honorius Houngbedji, Rudolf Vos\\xc3\\xa1tka, Katar\\xc3\\xadna Vor\\xc4\\x8d\\xc3\\xa1kov\\xc3\\xa1, Jarmila Vin\\xc5\\xa1ov\\xc3\\xa. 2-Hydroxy- Biomolecules. vol 9. issue 11. 2020-08-31. PMID:31694272.' |
2-hydroxy- the development of novel inhibitors of acetylcholinesterase (ache) and butyrylcholinesterase (buche) represents a viable approach to alleviate alzheimer's disease. |
2020-08-31 |
2023-08-13 |
Not clear |
| Shih-Chang Hsueh, Daniela Lecca, Nigel H Greig, Jia-Yi Wang, Warren Selman, Barry J Hoffer, Jonathan P Miller, Yung-Hsiao Chian. (-)-Phenserine Ameliorates Contusion Volume, Neuroinflammation, and Behavioral Impairments Induced by Traumatic Brain Injury in Mice. Cell transplantation. vol 28. issue 9-10. 2020-08-18. PMID:31177840. |
we have previously shown that (-)-phenserine (phen), an acetylcholinesterase inhibitor originally designed and tested in clinical phase iii trials for alzheimer's disease, can reduce neurodegeneration after tbi and reduce cognitive impairments induced by mild tbi. |
2020-08-18 |
2023-08-13 |
mouse |
| Mahboobeh Eslami, Navid Nezafat, Manica Negahdaripour, Younes Ghasem. Computational approach to suggest a new multi-target-directed ligand as a potential medication for Alzheimer's disease. Journal of biomolecular structure & dynamics. vol 37. issue 18. 2020-08-13. PMID:30689517. |
acetylcholinesterase (ache) enzyme and myeloid differentiation 2 protein (md2) are two critical proteins involved in alzheimer's disease (ad). |
2020-08-13 |
2023-08-13 |
Not clear |
| Miriama Simunkova, Saleh H Alwasel, Ibrahim M Alhazza, Klaudia Jomova, Vojtech Kollar, Miroslav Rusko, Marian Valk. Management of oxidative stress and other pathologies in Alzheimer's disease. Archives of toxicology. vol 93. issue 9. 2020-08-13. PMID:31440798. |
alzheimer's disease (ad) is a multifactorial neurodegenerative disorder, characterized by the formation, aggregation and accumulation of amyloid beta, perturbed metal (copper, iron and zinc) homeostasis, metal-induced oxidative stress, neuroinflammation, aberrant activity of acetylcholinesterase (ache) and other pathologies. |
2020-08-13 |
2023-08-13 |
Not clear |
| Nenad Bogdanovic, Oskar Hansson, Henrik Zetterberg, Hans Basun, Martin Ingelsson, Lars Lannfelt, Kaj Blenno. [Alzheimer's disease - the most common cause of dementia]. Lakartidningen. vol 117. 2020-08-10. PMID:32154904. |
current alzheimer's disease therapy is based on two classes of cognition-enhancing drugs: acetylcholinesterase inhibitor and nmda-receptor antagonist, which delays cognitive decline in most patients. |
2020-08-10 |
2023-08-13 |
Not clear |
| Ngo Thi Lan, Khanh B Vu, Minh Khue Dao Ngoc, Phuong-Thao Tran, Dinh Minh Hiep, Nguyen Thanh Tung, Son Tung Ng. Prediction of AChE-ligand affinity using the umbrella sampling simulation. Journal of molecular graphics & modelling. vol 93. 2020-06-22. PMID:31479951. |
acetylcholinesterase (ache) is characterized as a key target for designing inhibitors to prevent alzheimer's disease (ad). |
2020-06-22 |
2023-08-13 |
human |
| Lyubomir T Vezenkov, Daniela S Tsekova, Ivanka Kostadinova, Rositsa Mihaylova, Nikolay G Vassilev, Nikolai D Danche. Synthesis of New Galanthamine-Peptide Derivatives Designed for Prevention and Treatment of Alzheimer's Disease. Current Alzheimer research. vol 16. issue 3. 2020-06-16. PMID:30819081. |
although no effective treatment for the alzheimer's disease currently exist, some drugs acting as acetylcholinesterase inhibitors, like galanthamine have positively affected such patients. |
2020-06-16 |
2023-08-13 |
Not clear |
| Francesco Panza, Madia Lozupone, Vincenzo Solfrizzi, Mark Watling, Bruno P Imbimb. Time to test antibacterial therapy in Alzheimer's disease. Brain : a journal of neurology. vol 142. issue 10. 2020-06-15. PMID:31532495. |
while anti-amyloid-β therapies continue to be tested in prodromal patients with alzheimer's disease and in subjects at risk of developing alzheimer's disease, there is an urgent need to provide therapeutic support to patients with established alzheimer's disease for whom current symptomatic treatment (acetylcholinesterase inhibitors and n-methyl d-aspartate antagonist) provide limited help. |
2020-06-15 |
2023-08-13 |
human |
| Rafael E O Rocha, Leonardo H F Lim. Cooperative hydrogen bonds and mobility of the non-aromatic ring as selectivity determinants for human acetylcholinesterase to similar anti-Alzheimer's galantaminics: a computational study. Journal of biomolecular structure & dynamics. vol 37. issue 7. 2020-06-02. PMID:29697300. |
galantamine (gnt) is a natural alkaloid inhibitor of acetylcholinesterase and is presently one of the most used drugs in the treatment against alzheimer's disease during both the initial and intermediate stages. |
2020-06-02 |
2023-08-13 |
human |
| Xinhua Zhou, Wei Xiao, Zhiyang Su, Jiehong Cheng, Chengyou Zheng, Zaijun Zhang, Yuqiang Wang, Liang Wang, Benhong Xu, Shupen Li, Xifei Yang, Maggie Pui Man Ho. Hippocampal Proteomic Alteration in Triple Transgenic Mouse Model of Alzheimer's Disease and Implication of PINK 1 Regulation in Donepezil Treatment. Journal of proteome research. vol 18. issue 4. 2020-06-01. PMID:30484658. |
donepezil is a clinically approved acetylcholinesterase inhibitor (achei) for cognitive improvement in alzheimer's disease (ad). |
2020-06-01 |
2023-08-13 |
mouse |
| Sonal Setya, Tushar Madaan, Bal Kishen Razdan, Mamta Farswan, Sushama Talegaonka. Design and Development of Novel Transdermal Nanoemulgel for Alzheimer's Disease: Pharmacokinetic, Pharmacodynamic and Biochemical Investigations. Current drug delivery. vol 16. issue 10. 2020-05-27. PMID:31642410. |
oral treatment with tacrine hydrochloride; a reversible inhibitor of acetylcholinesterase, finds limited use in alzheimer's disease due to frequent dosing, hepatotoxicity and extensive pre-systemic metabolism. |
2020-05-27 |
2023-08-13 |
Not clear |
| Domink Glinz, Viktoria L Gloy, Andreas U Monsch, Reto W Kressig, Chandni Patel, Kimberly Alba McCord, Zanfina Ademi, Yuki Tomonaga, Matthias Schwenkglenks, Heiner C Bucher, Heike Raat. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis. Swiss medical weekly. vol 149. 2020-05-11. PMID:31269225. |
acetylcholinesterase inhibitors combined with memantine for moderate to severe alzheimer's disease: a meta-analysis. |
2020-05-11 |
2023-08-13 |
Not clear |
| Domink Glinz, Viktoria L Gloy, Andreas U Monsch, Reto W Kressig, Chandni Patel, Kimberly Alba McCord, Zanfina Ademi, Yuki Tomonaga, Matthias Schwenkglenks, Heiner C Bucher, Heike Raat. Acetylcholinesterase inhibitors combined with memantine for moderate to severe Alzheimer's disease: a meta-analysis. Swiss medical weekly. vol 149. 2020-05-11. PMID:31269225. |
the clinical efficacy and safety of combination therapy with acetylcholinesterase inhibitor (achei) and memantine compared to achei or memantine alone in patients with alzheimer’s disease is inconclusive. |
2020-05-11 |
2023-08-13 |
Not clear |
| Rex M Philpot, M Ficken, B E Johns, M E Engberg, L Wecke. Spatial memory deficits in mice induced by chemotherapeutic agents are prevented by acetylcholinesterase inhibitors. Cancer chemotherapy and pharmacology. vol 84. issue 3. 2020-05-11. PMID:31302713. |
these studies determined whether the acetylcholinesterase inhibitors, donepezil and galantamine, both of which are approved for the treatment of cognitive deficits in alzheimer's disease, can prevent or reverse spatial memory deficits in mice induced by cyclophosphamide and doxorubicin, cytotoxic agents commonly used to treat breast cancer. |
2020-05-11 |
2023-08-13 |
mouse |
| Saida Haider, Laraib Liaquat, Saara Ahmad, Zehra Batool, Rafat Ali Siddiqui, Saiqa Tabassum, Sidrah Shahzad, Sahar Rafiq, Narjis Na. Naringenin protects AlCl3/D-galactose induced neurotoxicity in rat model of AD via attenuation of acetylcholinesterase levels and inhibition of oxidative stress. PloS one. vol 15. issue 1. 2020-04-24. PMID:31945778. |
currently prescribed medications for the treatment of alzheimer's disease (ad) that are based on acetylcholinesterase inhibition only offer symptomatic relief but do not provide protection against neurodegeneration. |
2020-04-24 |
2023-08-13 |
rat |
| Penislusshiyan Sakayanathan, Chitra Loganathan, Saravanan Kandasamy, Rajesh V Ramanna, Kumaradhas Poomani, Palvannan Thayumanava. In vitro and in silico analysis of novel astaxanthin-s-allyl cysteine as an inhibitor of butyrylcholinesterase and various globular forms of acetylcholinesterases. International journal of biological macromolecules. vol 140. 2020-04-16. PMID:31442505. |
in alzheimer's disease (ad) and diabetes-associated cognitive decline, the acetylcholinesterase (ache) and butyrylcholinesterase (bche) activity is increased. |
2020-04-16 |
2023-08-13 |
human |
| El Hassen Mokrani, Abderrahmane Bensegueni, Ludovic Chaput, Claire Beauvineau, Hanane Djeghim, Liliane Mouawa. Identification of New Potent Acetylcholinesterase Inhibitors Using Virtual Screening and in vitro Approaches. Molecular informatics. vol 38. issue 5. 2020-04-15. PMID:30725535. |
acetylcholinesterase (ache) is currently the most favorable target for the symptomatic treatment and reduction of alzheimer's disease (ad). |
2020-04-15 |
2023-08-13 |
Not clear |